TrialBlood advances2022

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.

Elisabetta Metafuni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.